Section 137 vicarious liability — defence checklist (19 items) □ All accused (company + individuals) identified □ Basis of vicarious liability (sub-s. (1) / (2) / (3)) for each individual mapped □ Senior criminal counsel for company…
137
Section 137 vicarious liability — defence checklist (19 items) □ All accused (company + individuals) identified □ Basis of vicarious liability (sub-s. (1) / (2) / (3)) for each individual mapped □ Senior criminal counsel for company…
Section 137 vicarious liability — defence checklist (19 items)
Section 137 vicarious liability — defence checklist (19 items)
□ All accused (company + individuals) identified
□ Basis of vicarious liability (sub-s. (1) / (2) / (3)) for each individual mapped
□ Senior criminal counsel for company engaged
□ Personal counsel for each director / officer engaged
□ Privilege framework documented across counsel
□ S.M.S. Pharmaceuticals pleading-sufficiency test applied to complaint
□ Due-diligence documentary evidence assembled
□ Absence-of-knowledge evidence (non-executive directors) prepared
□ Director-resignation documentation reviewed (if applicable)
□ Commissioner sanction file demanded for each accused
□ Sanction-quality challenge per accused prepared
□ Discharge application under CrPC s. 227 / 239 filed for each accused
□ Pre-arrest bail filed for cognizable cases
□ Section 138 compounding coordinated evaluation completed
□ CrPC s. 313 statement drafted for each accused with personal counsel
□ D&O insurance coverage reviewed and claim notice filed
□ Cross-examination strategy for vicarious-liability witnesses prepared
□ Trial defence strategy outlined for each accused
□ Appellate options framework prepared for each accused
Worked examples — five live scenarios
Example 1 — Non-executive director discharge
Facts: A is non-executive director of X Ltd; prosecution under s. 137 alleges vicarious liability. A had no operational role.
Step 1: S.M.S. Pharmaceuticals framework — bald averment insufficient.
Step 2: Documentary evidence: A's role limited to board attendance; no operational responsibility.
Step 3: Sub-s. (4) defence — absence of knowledge AND due diligence (relied on management reports).
Step 4: File discharge application under CrPC s. 239.
Step 5: Magistrate discharges A — finds no 'in charge and responsible' basis pleaded.
Result: A discharged. Demonstrates the strength of S.M.S. Pharmaceuticals discharge framework for non-executive directors.
Example 2 — MD vicarious liability — due-diligence defence
Facts: B is MD of Y Ltd; faces s. 137 vicarious liability for s. 132(1)(b) prosecution. B contests on due-diligence.
Step 1: B was 'in charge and responsible' — sub-s. (1) applies.
Step 2: Sub-s. (4) defence — due diligence: comprehensive compliance regime documented.
Step 3: Compliance manuals; SOPs; supplier KYC; internal audit; external audit clean opinion.
Step 4: Specific compliance steps for invoice / ITC verification — documented.
Step 5: Trial — defence evidence presented; cross-examination shows reasonable systems.
Result: Court holds due-diligence defence succeeds; B acquitted. Y Ltd's corporate prosecution continues separately. Demonstrates due-diligence framework for executive directors.
Example 3 — Coordinated compounding for all accused
Facts: C Ltd's prosecution names 5 directors / officers. Corporate strategy — compound under s. 138.
Step 1: Compounding evaluation — Rs. 5 crore @ 50% = Rs. 2.5 crore.
Step 2: Compounding extinguishes prosecution for all accused.
Step 3: Cost-benefit — compounding cheaper than individual trial costs.
Step 4: Coordinated compounding agreement; all accused.
Step 5: Prosecution closed for all.
Result: Coordinated compounding paid; criminal liability extinguished for all. Demonstrates strategic value of coordinated compounding in multi-accused matters.
Example 4 — Sub-s. (3) partner liability
Facts: D Firm faces s. 132 prosecution; partners E and F charged under sub-s. (3).
Step 1: F is sleeping partner; no operational involvement.
Step 2: F's discharge under sub-s. (4) — absence of knowledge.
Step 3: E is managing partner — operational responsibility.
Step 4: E's defence — due-diligence on compliance regime.
Step 5: Trial — E acquitted on due-diligence; F discharged earlier.
Result: Both partners free of conviction. Demonstrates sub-s. (3) operation with sub-s. (4) defence for partnership firms.
Example 5 — Director-resigned defence
Facts: G resigned from H Ltd's board 6 months before the offence date. Prosecution under s. 137 includes G.
Step 1: Form DIR-12 filed; resignation documented.
Step 2: G was not director at time of offence.
Step 3: Sub-s. (1) inapplicable — not 'in charge and responsible' at time of offence.
Step 4: Sub-s. (2) inapplicable — no consent / connivance / negligence (not in office).
Step 5: File discharge application; Magistrate discharges G.
Result: G discharged. Demonstrates the value of resignation timing and documentation.
Planning and litigation strategy
• For corporate compliance, build comprehensive documentation supporting due-diligence under sub-s. (4).
• Maintain board minutes showing compliance discussions and risk-management decisions.
• Document delegation of authority — clarify who is 'in charge and responsible' for what.
• Periodic compliance audits with documented findings — supports due-diligence defence.
• Train senior management on s. 137 personal-exposure landscape.
• For non-executive / independent directors, document information flow and oversight role.
• Maintain D&O insurance coverage; review exclusions periodically.
• On director resignation, ensure prompt Form DIR-12 filing and acknowledgement.
• For high-risk areas, build redundancy in compliance documentation.
• Engage senior criminal counsel early for any matter approaching s. 132 prosecution.
• Coordinate corporate counsel and individual personal counsel for officers.
• Build Commissionerate-level intelligence on s. 137 invocation patterns.
• Monitor S.M.S. Pharmaceuticals jurisprudence developments — informs discharge strategy.
• Maintain documentation supporting absence-of-knowledge defence for non-operational officers.
• Document compliance regime evolution — supports temporal due-diligence narrative.
Litigation defence
• Frame each accused's defence individually — personal counsel essential.
• On complaint sufficiency, anchor in S.M.S. Pharmaceuticals — specific role averment required.
• On due-diligence defence (sub-s. (4)(b)), assemble comprehensive compliance regime evidence.
• On absence-of-knowledge defence (sub-s. (4)(a)), build information-flow evidence.
• For non-executive directors, frame discharge application aggressively under S.M.S. Pharmaceuticals.
• For resigned directors, present Form DIR-12 and date documentation.
• Demand Commissioner sanction file for each accused; test application of mind under Saldanha.
• Coordinate corporate defence and individual defence; avoid contradictions.
• On compounding evaluation, consider coordinated extinguishment for all accused.
• On CrPC s. 313 statement, individual counsel engagement.
• Cross-examine prosecution witnesses on specifics of vicarious-liability allegations.
• On adverse Magistrate / Sessions Court outcomes, evaluate individual appellate options.
• Maintain documentary record of all proceedings for each accused.
• On regulatory disclosure obligations (SEBI listing), coordinate with company secretary.
• Build precedent track record of discharge / acquittal for institutional knowledge.
• Document lessons from each prosecution to harden future compliance posture.
Cross-references
• Section 132 — Punishment for certain offences — primary offence provision triggering s. 137.
• Section 133 — Officer-of-Department liability.
• Section 134 — Cognizance of offences — sanction quality interface.
• Section 135 — Presumption of culpable mental state — interacts with sub-s. (4).
• Section 136 — Relevancy of s. 70 statements in prosecution.
• Section 138 — Compounding — coordinated extinguishment for all accused.
• Section 69 — Power to arrest.
• Section 70 — Power to summon.
• Section 122 — Penalty for certain offences — civil-track penalty separate framework.
• Section 131 — Civil-criminal parallel preservation.
• Section 89 — Liability of directors of private company (civil-track) — related but distinct.
• Section 90 — Partners of firm (civil-track liability).
• Section 91 — Guardians, trustees, representatives (civil-track).
• Companies Act, 2013 — s. 166 fiduciary duties; s. 447 fraud offences; s. 164 disqualification.
• Negotiable Instruments Act, 1881 — s. 141 — pari materia vicarious liability.
• Customs Act, 1962 — s. 140 — pari materia.
• Central Excise Act, 1944 — s. 9AA — pari materia.
• Income-Tax Act, 1961 — s. 278B — pari materia.
• Limited Liability Partnership Act, 2008 — partner liability framework.
• Hindu Succession Act, 1956 — HUF karta authority.
• Indian Trusts Act, 1882 — trustee responsibilities.
• Code of Criminal Procedure, 1973 / BNSS — procedural framework.
• Article 14 of Constitution — equality / proportionality.
• Article 21 of Constitution — personal liberty; fair-trial standards.
• Article 226 of Constitution — High Court writ jurisdiction.
• S.M.S. Pharmaceuticals Ltd v Neeta Bhalla (2005) 8 SCC 89 — vicarious-liability pleading requirements.
• K.K. Ahuja v V.K. Vora (2009) 10 SCC 48 — director-level vicarious liability scope.
• Mafatlal Industries (1997) 5 SCC 536 — procedural safeguards.
• Hindustan Steel (1970) 1 SCR 753 — bona-fide-belief defence.
• CST v Sanjiv Fabrics (2010) 9 SCC 630 — mens-rea standard.
• Maneka Gandhi (1978) 1 SCC 248 — fair procedure.
• State of Bihar v J.A.C. Saldanha (1980) 1 SCC 554 — sanction quality.